Amgen Inc. Share Price

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 14/06/2024 BST 5-day change 1st Jan Change
298.6 USD +0.04% Intraday chart for Amgen Inc. -2.10% +3.68%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 33B 2,602B Sales 2025 * 33.97B 2,678B Capitalization 160B 12,631B
Net income 2024 * 4.11B 324B Net income 2025 * 6.21B 490B EV / Sales 2024 * 6.33 x
Net Debt 2024 * 48.6B 3,832B Net Debt 2025 * 43.61B 3,439B EV / Sales 2025 * 6 x
P/E ratio 2024 *
37.6 x
P/E ratio 2025 *
24.2 x
Employees 26,700
Yield 2024 *
3.09%
Yield 2025 *
3.33%
Free-Float 99.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.04%
1 week-2.10%
Current month-2.36%
1 month-6.40%
3 months+11.06%
6 months+8.41%
Current year+3.68%
More quotes
1 week
295.30
Extreme 295.3
305.53
1 month
295.30
Extreme 295.3
316.67
Current year
260.68
Extreme 260.68
329.72
1 year
218.44
Extreme 218.44
329.72
3 years
198.64
Extreme 198.64
329.72
5 years
173.12
Extreme 173.12
329.72
10 years
114.93
Extreme 114.93
329.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 31/05/06
Director of Finance/CFO 65 22/10/19
Chief Tech/Sci/R&D Officer 52 12-17
Members of the board TitleAgeSince
Director/Board Member 67 02/02/17
Director/Board Member 68 13/10/16
Director/Board Member 69 31/12/02
More insiders
Date Price Change Volume
14/06/24 298.6 +0.04% 1,713,616
13/06/24 298.5 -0.86% 1,732,666
12/06/24 301.1 +0.13% 1,640,098
11/06/24 300.7 -1.32% 1,740,194
10/06/24 304.7 -0.10% 1,992,837

Delayed Quote Nasdaq, June 14, 2024 at 09:00 pm

More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
298.6 USD
Average target price
316.4 USD
Spread / Average Target
+5.97%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW